Fulcrum Therapeutics Inc (NAS:FULC)
$ 4.79 -0.05 (-1.03%) Market Cap: 258.37 Mil Enterprise Value: 12.97 Mil PE Ratio: 0 PB Ratio: 1.00 GF Score: 50/100

Fulcrum Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 12, 2023 / 12:30AM GMT
Release Date Price: $13.97 (+6.32%)
Lalita Sundarrajan

Hi, everyone. Good afternoon, and welcome to the 41st Annual JPMorgan Healthcare Conference. My name is Lalita Sundarrajan, and I'm an associate here on the JPMorgan healthcare banking team. It's my absolute pleasure to introduce our speaker for today's presentation, CEO of Fulcrum Therapeutics, Robert Gould. He's joined on stage by CFO, Esther Rajavelu; and Chief Medical Officer, Santiago Arroyo. With that, Robert, I'll turn it over to you.

Robert J. Gould
Fulcrum Therapeutics, Inc. - Interim CEO & Director

Well, thank you very much, and thank you to JPMorgan for the opportunity to present to you this afternoon. What we'll be looking at today is the progress we've made over the last year at Fulcrum Therapeutics and also looking forward to some of the highlights of what we anticipate coming in 2023. As such, I'll be presenting forward-looking statements.

Fulcrum was started about 7 years ago with the vision of treating genetically defined diseases with small molecules to change the lives of patients with genetically defined diseases

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot